<!DOCTYPE html>
<!-- saved from url=(0083)https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm -->
<html class="" data-reactroot=""><script async="false" type="text/javascript" src="chrome-extension://fnjhmkhhmkbjkkabndcnnogagogbneec/in-page.js"></script><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script src="./91.育亨宾 - 搜狗科学百科_files/analytics.js.download" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app218.us.archive.org';v.server_ms=259;archive_analytics.send_pageview({});});</script>
<script type="text/javascript" src="./91.育亨宾 - 搜狗科学百科_files/bundle-playback.js.download" charset="utf-8"></script>
<script type="text/javascript" src="./91.育亨宾 - 搜狗科学百科_files/wombat.js.download" charset="utf-8"></script>
<script type="text/javascript">
  __wm.init("https://web.archive.org/web");
  __wm.wombat("https://baike.sogou.com/kexue/d10091.htm","20221028215451","https://web.archive.org/","web","/_static/",
	      "1666994091");
</script>
<link rel="stylesheet" type="text/css" href="./91.育亨宾 - 搜狗科学百科_files/banner-styles.css">
<link rel="stylesheet" type="text/css" href="./91.育亨宾 - 搜狗科学百科_files/iconochive.css">
<!-- End Wayback Rewrite JS Include -->
<meta name="save" content="history"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="baidu-site-verification" content="VWGb6TyYx8"><meta content="育亨宾 - 搜狗科学百科" name="keywords"><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"><meta http-equiv="x-dns-prefetch-control" content="on"><meta name="server" baike="235" ip="210" env="online"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://cache.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://hhy.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://pic.baike.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://ugc.qpic.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://xui.ptlogin2.qq.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://q1.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://q2.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://q3.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://q4.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://q.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://img01.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://img02.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://img03.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215451/https://img04.sogoucdn.com/"><link rel="Shortcut Icon" href="https://web.archive.org/web/20221028215451im_/https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link rel="Bookmark" href="https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link href="./91.育亨宾 - 搜狗科学百科_files/base_b849887.css" rel="stylesheet"><link href="./91.育亨宾 - 搜狗科学百科_files/detail_378aed5.css" rel="stylesheet"><link href="./91.育亨宾 - 搜狗科学百科_files/inviteAudit_7894507.css" rel="stylesheet"><link rel="stylesheet" href="./91.育亨宾 - 搜狗科学百科_files/highlight.min.css"><title>育亨宾 - 搜狗科学百科</title><style>.onekey-close {
	position: absolute;
	top: 16px;
	right: 16px;
	width: 24px;
	height: 24px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	text-indent: -999em;
	background-size: 84px;
	background-position: -63px 0;
}

.onekey-login {
	position: absolute;
	top: 16.4%;
	left: 0;
	right: 0;
	width: 100%;
}

/* .onekey-login-img {
    width: 75px;
    height: 75px;
    background: url("https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/images/sprite_wap_baike.png") no-repeat;
    background-size: 100px 91px;
    background-position: 0 0;
    background-repeat: no-repeat;
    margin: 0 auto;
} */

.onekey-login-title {
	text-align: center;
	padding-bottom: 3px;
	font-size: 21px;
	font-weight: bold;
	line-height: 30px;
	color: #000;
}

.onekey-login-txt {
	text-align: center;
	font-family: PingFangSC;
	font-size: 14px;
	line-height: 20px;
	color: #8f8f8f;
}

.onekey-login-qq,
.onekey-login-wx,
.onekey-login-phone {
	display: block;
	width: 245px;
	height: 54px;
	border-radius: 45px;
	text-align: center;

	margin: 0 auto;
	font-size: 17px;
	line-height: 24px;
	color: #000;
	/* padding: 16px 77px; */
	border-radius: 12px;
	border: solid 1px #e0e0e0;
}
.onekey-qq-content,
.onekey-vx-content,
.onekey-phone-content {
	display: inline-block;
	margin-top: 16px;
}
.onekey-qq-content {
	padding: 0 5px;
}

.onekey-login-qq {
	margin-top: 48px;
	margin-bottom: 24px;
}

.onekey-login-qq:before {
	display: inline-block;
	content: "";
	width: 20px;
	height: 20px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 80px;
	background-position: -20px 0;
	vertical-align: top;
	margin: 17px 8px 0 0;
}

.onekey-login-wx {
	margin-bottom: 24px;
}

.onekey-login-wx:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: 0 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-login-phone {
}

.onekey-login-phone:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: -42px 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-fixed {
	z-index: 100;
	position: fixed;
	top: 0;
	bottom: 0;
	left: 0;
	right: 0;
	background: #fff;
	width: 100%;
	height: 100%;
}

.onekey-fixed.forbid {
	z-index: 100;
	position: fixed;
	top: auto;
	bottom: 68px;
	left: 9%;
	right: 0;
	background: rgba(0, 0, 0, 0.7);
	width: 82%;
	height: 43px;
	border-radius: 25px;
	color: #ffffff;
}
.onekey-login-title.forbid {
	text-align: center;
	padding-bottom: 3px;
	font-size: 14px;
	font-weight: normal;
	line-height: 30px;
	color: white;
}
</style><style>#login_mask {
  background: #000;
  opacity: 0.5;
  filter: alpha(opacity=50);
  position: fixed;
  /*fixed好像在哪个IE上有BUG，先用用*/
  left: 0;
  top: 0;
  z-index: 999;
  height: 100%;
}

#login_iframe_container {
  position: fixed;
  width: 550px;
  height: 360px;
  z-index: 1020;
  background-color: #ffffff;
}

@media screen and (max-width: 828px) {
  #login_iframe_container {
    top: 50% !important;
    left: 50% !important;
    transform: translate(-50%, -50%);
  }
}

#login_iframe_container.new-login {
  width: 550px;
  height: 360px;
  background-image: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/background_2a4a8a6.png);
}

#login_iframe_container.new-login.no-bg {
  background: #fff;
}

#login_iframe_container.new-login .login-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 30px;
  letter-spacing: 0.19px;
  color: #ffffff;
  margin-top: 62px;
}
#login_iframe_container.new-login .forbid-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 24px;
  letter-spacing: 0.19px;
  color: #333333;
  margin-top: 150px;
}

#login_iframe_container.new-login.no-bg .login-title {
  color: #333333;
}

#login_iframe_container.new-login .login-subtitle {
  width: 100%;
  height: 18px;
  line-height: 18px;
  font-size: 13px;
  letter-spacing: 0.08px;
  color: #ffffff;
  text-align: center;
  margin-top: 9px;
  margin-bottom: 43px;
}

#login_iframe_container.new-login.no-bg .login-subtitle {
  color: #999999;
}

#login_iframe_container.new-login .login-subtitle::before {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: -5px;
}

#login_iframe_container.new-login .login-subtitle::after {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: 5px;
}

#login_iframe_container.new-login.no-bg .login-subtitle::before {
  background-color: #999999;
}

#login_iframe_container.new-login.no-bg .login-subtitle::after {
  background-color: #999999;
}

#login_iframe_container.new-login .close-btn {
  position: absolute;
  top: 20px;
  right: 20px;
  width: 12px;
  height: 12px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -59px -10px;
  background-size: 81px 91px;
  cursor: pointer;
}

#login_iframe_container.new-login .login-btn {
  width: 220px;
  height: 47px;
  border-radius: 24px;
  border: solid 1px #dddddd;
  background-color: #ffffff;
  margin: 0 auto;
  margin-top: 28px;
  position: relative;
  display: block;
}

#login_iframe_container.new-login .login-btn .login-icon {
  position: absolute;
}

#login_iframe_container.new-login .login-btn .login-text {
  width: 61px;
  height: 47px;
  line-height: 47px;
  vertical-align: middle;
  font-size: 15px;
  letter-spacing: 0.1px;
  color: #666666;
  position: absolute;
  right: 62px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-icon {
  width: 22px;
  height: 27px;
  top: 10px;
  left: 67px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -54px;
  background-size: 81px 91px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-text {
  right: 59px;
}

#login_iframe_container.new-login .login-btn.wechat-btn .login-icon {
  width: 29px;
  height: 24px;
  top: 12px;
  left: 62px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -10px;
  background-size: 81px 91px;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style></head><body class=""><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
</style>
<script>__wm.rw(0);</script>
<div id="wm-ipp-base" lang="en" style="display: block; direction: ltr;">
</div><div id="wm-ipp-print">The Wayback Machine - https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm</div>
<script type="text/javascript">//<![CDATA[
__wm.bt(675,27,25,2,"web","https://baike.sogou.com/kexue/d10091.htm","20221028215451",1996,"/_static/",["/_static/css/banner-styles.css?v=S1zqJCYt","/_static/css/iconochive.css?v=qtvMKcIJ"], false);
  __wm.rw(1);
//]]></script>
<!-- END WAYBACK TOOLBAR INSERT --><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('406da213f81743bbaa8e87878372cbdd') window._gtag.traceId = '406da213f81743bbaa8e87878372cbdd';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="https://web.archive.org/web/20221028215451/https://www.sogou.com/web?query=">网页</a></li><li><a href="https://web.archive.org/web/20221028215451/https://weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="https://web.archive.org/web/20221028215451/https://zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="https://web.archive.org/web/20221028215451/https://pic.sogou.com/pics?query=">图片</a></li><li><a href="https://web.archive.org/web/20221028215451/https://v.sogou.com/v?query=">视频</a></li><li><a href="https://web.archive.org/web/20221028215451/https://mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="https://web.archive.org/web/20221028215451/https://hanyu.sogou.com/">汉语</a></li><li><a href="https://web.archive.org/web/20221028215451/https://wenwen.sogou.com/">问问</a></li><li><a href="https://web.archive.org/web/20221028215451/https://www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header"><div class="header-wrap"><a class="header-logo" href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"><form><input id="searchInput" class="query" type="text" placeholder="搜科学领域专业百科词条" name="query" autocomplete="off" value="" control-id="ControlID-1"><a href="javascript:;" class="query-search"></a></form></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>育亨宾</h1><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="52079316648904704"><div class="text_img ed_imgfloat_right"><a class="ed_image_link" data-src="https://img03.sogoucdn.com/app/a/200698/360_360_20200908155022-835215598.jpg" data-bigsrc="https://img03.sogoucdn.com/app/a/200698/360_360_20200908155022-835215598.jpg?width=227&amp;height=174&amp;titlename=&amp;w=360&amp;h=360" title="点击查看大图" data-w="360" data-h="360" style="background-image:url(https://web.archive.org/web/20221028215451im_/https://img03.sogoucdn.com/app/a/200698/360_360_20200908155022-835215598.jpg)" href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#!"></a></div><div><p>育亨宾(/joʊˈhɪmbiːn/)，<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_1" class="kx_ref">[1]</a></sup> 是一种吲哚醌类生物碱，来源于非洲育亨宾树和名字与其无关的南美洲白树的树皮。育亨宾是一种α-2肾上腺素受体阻断剂，已被用于多种研究项目。育亨宾是一种兽药，用于让狗和鹿从镇静中恢复。虽然育亨宾在一些哺乳动物身上使用时有春药的作用，但在人类身上却没有此类功效。它已被用作治疗勃起功能障碍，但据报道其临床作用不大，并且已被PDE5抑制剂类药物所取代。据称，育亨宾树提取物的物质已经作为膳食补充剂进行销售，但是它们含有的育亨宾量是非常不确定的（如果有的话）；没有公开的科学证据支持其疗效。</p></div></div><div id="catalog"><h2 class="title2">目录<a href="javascript:" class="detail-edit">编辑</a></h2><div class="catalog_wrap" style=""><ul class="catalog_list col3"><li><span class="order">1</span><a href="javascript:" data-level="1" data-id="14994942346658069">使用</a></li><li><span class="order">2</span><a href="javascript:" data-level="1" data-id="14994942346658070">育亨宾和育亨宾树</a></li><li class="secondary_catalog"><span>2.1 </span><a href="javascript:" data-id="14994942346658070">混淆</a></li><li class="secondary_catalog"><span>2.2 </span><a href="javascript:" data-id="14994942346658070">对性功能的影响</a></li><li class="secondary_catalog"><span>2.3 </span><a href="javascript:" data-id="14994942346658070">育亨宾和膳食补充剂</a></li><li><span class="order">3</span><a href="javascript:" data-level="1" data-id="14994942363435268">毒性</a></li></ul><ul class="catalog_list col3"><li><span class="order">4</span><a href="javascript:" data-level="1" data-id="14994942363435269">提取物和化学性质</a></li><li><span class="order">5</span><a href="javascript:" data-level="1" data-id="14994942363435270">药理学</a></li><li><span class="order">6</span><a href="javascript:" data-level="1" data-id="14994942380212489">研究</a></li><li><span class="order">7</span><a href="javascript:" data-level="1" data-id="14994942380212490">育亨宾的生物来源；可持续性</a></li><li class="secondary_catalog"><span>7.1 </span><a href="javascript:" data-id="14994942380212490"><i>Pausinystalia johimbe</i></a></li><li class="secondary_catalog"><span>7.2 </span><a href="javascript:" data-id="14994942380212490"><i>白雀麦Aspidosperma quebracho-blanco</i></a></li></ul><ul class="catalog_list col3"><li class="secondary_catalog"><span>7.3 </span><a href="javascript:" data-id="14994942380212490">其他植物</a></li><li><span class="order">8</span><a href="javascript:" data-level="1" data-id="14994942380212491">添加剂</a></li><li><span class="order">9</span><a href="javascript:" data-level="1" data-id="references">参考文献</a></li></ul></div></div><div id="paragraphs"><div><div id="par_14994942346658069"><h2 class="title">1 使用<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>育亨宾是一种兽药，用于让狗和鹿从赛拉嗪的镇静作用中恢复。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_2" class="kx_ref">[2]</a></sup> 它被用作研究用试剂。在美国，它是针对男性勃起功能障碍的处方药，但现在很少使用了。</p></div></div><div id="par_14994942346658070"><h2 class="title">2 育亨宾和育亨宾树<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>2.1 <span>混淆</span></h3><p></p><p>育亨宾不应该和育亨宾树混淆，<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_3" class="kx_ref">[3]</a></sup> 但经常发生此类混淆。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_4" class="kx_ref">[4]</a></sup> </p><p>育亨宾（Yohimbe）是育亨宾树树种（P. johimbe）的通用英文名称，也是由其树皮制成的药物制剂的名称，作为壮阳药出售。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_5" class="kx_ref">[5]</a></sup> 相比之下，育亨宾（yohimbine）是一种纯生物碱，可以从育亨宾树皮中分离出来。</p><p>育亨宾只是从育亨宾树皮中分离出的55种吲哚生物碱之一；<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_6" class="kx_ref">[6]</a></sup> 并且，尽管它被描述为其中最活跃的组分，<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_7" class="kx_ref">[7]</a></sup> 但它仅占总生物碱含量的15%。 其他生物碱包括萝芙木碱、棒状碱和阿吉马利辛； 树皮中还含有其他组分未知的非生物碱。</p><p>因此，育亨宾是一种复杂的混合物，对它的研究远不如育亨宾这种纯化合物彻底。 药用级育亨宾通常以盐酸盐的形式出现，<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_8" class="kx_ref">[8]</a></sup> 更易溶解。</p><p></p><h3>2.2 <span>对性功能的影响</span></h3><p></p><p><strong>历史、研究和文献</strong></p><p>育亨宾在民间医学中被用作壮阳药。根据2010年美国国立卫生研究院的Joseph M. Betz撰写的百科全书文章，1900年，它引起了德国科学界的兴趣，最初的一份报告称育亨宾对动物和人类有很强的壮阳作用。 人们的注意力很快从这种植物转移到它的活性成分上，尤其是是育亨宾。 <sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_9" class="kx_ref">[9]</a></sup> </p><p>也许正是由于这一趋势，在文献中找不到关于育亨宾树皮或其提取物对人类性行为影响的研究报告...因此，任何关于使用育亨宾树皮提高性能力的讨论都是以民间传说开始和结束的。</p><p>相比之下，关于育亨宾这个物质的文献“相当丰富”。</p><p>育亨宾的后续研究虽然证实它在动物身上（包括老鼠、狗和金仓鼠）有壮阳药的作用，但在人类身上却没有。但是根据Betz的研究，实验</p><p>表明即使用在性疲惫的大鼠身上也会增加性欲，因为它对大脑蓝斑中发现的中枢α2-肾上腺素受体起作用。对大脑肾上腺素受体的阻断似乎逆转了调节阴茎勃起和维持消肿的中枢负反馈机制...育亨宾不会增加人类临床试验中的性欲。来自人类和动物临床研究的综合证据表明，育亨宾在刺激人类性行为方面的效果远远不如大鼠。对这一发现的一个可能的解释是人类的性行为存在着比老鼠更复杂的多重抑制控制，也就是说，人类对性的认知远比在动物身上观察到的基本基于本能的功能更重要。</p><p><strong>临床疗效</strong></p><p>育亨宾已经被用来治疗女性性功能障碍，但是很少有临床试验的报道，而且这些试验并没有显示它优于安慰剂。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_10" class="kx_ref">[10]</a></sup> 关于男性勃起功能障碍的治疗，Tam等人(2001年)的一篇综述文章总结道：</p><p>尽管它耐受性好且安全，即使大大超出了可能的治疗范围，但很明显，在一般勃起功能障碍人群中作为单一疗法的疗效可能不大。</p><p>根据贝茨(2010年)的说法，</p><p>现代的共识似乎是纯化合物育亨宾对某些男性的某些轻度勃起功能障碍有效，但不能作为壮阳药。</p><p>安德森在2011年的一篇综述中说：</p><p>育亨宾对不同类型的勃起功能障碍患者的效果已经在几个对照试验中被研究，但效果并不明显...不能排除口服育亨宾对某些勃起功能障碍患者可能有有益的效果。然而，由于结果相互矛盾，目前在大多数勃起功能障碍治疗指南中并不建议这样做。</p><p>育亨宾已经被西地那非(如伟哥)和其他PDE5抑制剂药物所取代。处方药现在很少见，大多数美国制药商已经停止生产处方胶囊和片剂。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_7" class="kx_ref">[7]</a></sup> </p><p></p><h3>2.3 <span>育亨宾和膳食补充剂</span></h3><p></p><p>在美国，“育亨宾”制剂作为增强性欲、减肥和健美的辅助食品出售；但是“几乎没有关于育亨宾的公开研究支持这些或任何其他说法”。 通常，这些产品明确声称含有育亨宾。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_7" class="kx_ref">[7]</a></sup> </p><p>科恩等人发现，在美国实体店销售的品牌样品中，育亨宾的含量变化很大，有时甚至根本不含育亨宾。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_7" class="kx_ref">[7]</a></sup> 标签声明往往具有误导性。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_7" class="kx_ref">[7]</a></sup> 其他实验室也报告了在美国，其他国家和互联网上销售的产品的类似结果。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_11" class="kx_ref">[11]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_12" class="kx_ref">[12]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_13" class="kx_ref">[13]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_14" class="kx_ref">[14]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_15" class="kx_ref">[15]</a></sup> 一项研究发现，许多品牌的“育亨宾”可能最初并不是来自于育亨宾树。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_16" class="kx_ref">[16]</a></sup> 根据另一个消息来源，在西非（育亨宾树生长的地方）出售育亨宾的市场上，育亨宾经常掺杂其他种类的育亨宾属类树含有的少量育亨宾。 即使在真正的育亨宾树皮中发现的生物碱的量也有很大差异，这取决于树皮的来源（根，茎，枝，高度等）。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_17" class="kx_ref">[17]</a></sup> </p><p>一些在场外销售的品牌被发现每剂育亨宾的含量超过标准药物剂量；<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_7" class="kx_ref">[7]</a></sup> 然而，在美国，药品受到严格的药品监管制度的制约。未经食品和药物管理局许可，在州际贸易中引入或运送“药物”是非法的。美国食品和药物管理局声称，一些含育亨宾的产品是“药物”，因为它们的推广显示表示“它们旨在用于治疗、缓解、治疗或预防疾病”:《美国法典》第21篇第321(g)(1)(B)节。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_18" class="kx_ref">[18]</a></sup> 然而，法律立场并不完全明确，<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_19" class="kx_ref">[19]</a></sup> 截至2019年2月1日，似乎没有任何成功起诉的记录。</p><p>由于缺乏育亨宾的可靠科学数据，欧洲食品安全管理局食品添加剂小组认定，欧洲食品安全局食品添加剂专家组确定无法就其安全性做出结论，也无法建立一个基于健康准则的指导值。他们写道：</p><p>总体而言，缺失信息包括育亨宾树皮及其制剂的组成和规格的定量数据，用于食品和食品补充剂，包括育亨宾以外的其他生物碱，育亨宾树皮提取物中活性成分的生物利用度数据，育亨宾树皮和育亨宾树皮主要生物碱的具体制剂的毒性数据，特别是亚慢性毒性、遗传毒性和生殖毒性数据。</p></div></div><div id="par_14994942363435268"><h2 class="title">3 毒性<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>根据剂量的不同，育亨宾可以增加或降低全身血压(血管收缩或血管舒张)。因为育亨宾对α2受体的亲和力最高，所以小剂量的育亨宾可以通过引起相对选择性的α2阻滞来增加血压。尽管亲和力较低，育亨宾也与α1受体相互作用；因此，在较高剂量下，可能会出现α1阻滞，并超过α2阻滞的效果，导致潜在的血压下降隐患。 口服高剂量育亨宾可能会产生许多副作用，如心率加快、刺激过度、血压异常、冷汗和失眠。</p></div></div><div id="par_14994942363435269"><h2 class="title">4 提取物和化学性质<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>育亨宾树(Pausinystalia johimbe)是一种生长在西非和中非的树；<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_20" class="kx_ref">[20]</a></sup>育亨宾最初是由阿道夫·斯皮格尔于1896年从育亨宾树皮中提取的。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_21" class="kx_ref">[21]</a></sup> (事实上，它早些时候就已经从南美的白树树皮中分离出来，并被命名为白坚木碱，但这一点被忽略了)。1943年，Witkop提出育亨宾的正确结构。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_22" class="kx_ref">[22]</a></sup> 十五年后，尤金·范·塔梅伦(Eugene van Tamelen)领导的团队利用23步合成法首次实现育亨宾全合成。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_23" class="kx_ref">[23]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_24" class="kx_ref">[24]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_25" class="kx_ref">[25]</a></sup> </p></div></div><div id="par_14994942363435270"><h2 class="title">5 药理学<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>育亨宾对α2肾上腺素能受体具有高亲和力，对α1受体、5-HT1A、5-HT1B、5-HT1D、5-HT1F、5-HT2B和多巴胺D2受体具有中等亲和力，对5-HT1E、5-HT2A、5-HT5A、5-HT7和多巴胺D3受体具有弱亲和力。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_26" class="kx_ref">[26]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_27" class="kx_ref">[27]</a></sup> 它在α1肾上腺素、α2肾上腺素、5-HT1B、5-HT1D、5-HT2A、5-HT2B和多巴胺D2上表现为拮抗剂，在5-HT1A上表现为部分激动剂。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_26" class="kx_ref">[26]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_28" class="kx_ref">[28]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_29" class="kx_ref">[29]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_30" class="kx_ref">[30]</a></sup> 高浓度的育亨宾与血清素和多巴胺受体相互作用。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_31" class="kx_ref">[31]</a></sup> </p><p>
 </p><table class="wikitable sortable">
  <caption>
   药理概况
  </caption>
  <tbody>
   <tr>
    <th>分子靶</th>
    <th>亲合力<br>(千纳摩尔)<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_27" class="kx_ref">[27]</a></sup></th>
    <th>药理作用<br><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_26" class="kx_ref">[26]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_28" class="kx_ref">[28]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_29" class="kx_ref">[29]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_30" class="kx_ref">[30]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_32" class="kx_ref">[32]</a></sup></th>
    <th>种类</th>
    <th>来源</th>
   </tr>
   <tr>
    <td>SERT</td>
    <td>1,000</td>
    <td>抑制剂</td>
    <td>人类</td>
    <td>额叶皮层</td>
   </tr>
   <tr>
    <td>5-HT<sub>1A</sub></td>
    <td>346</td>
    <td>部分激动剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>5-HT<sub>1B</sub></td>
    <td>19.9</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>5-HT<sub>1D</sub></td>
    <td>44.3</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>5-HT<sub>1E</sub></td>
    <td>1,264</td>
    <td>未知的</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>5-HT<sub>1F</sub></td>
    <td>91.6</td>
    <td>未知的</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>5-HT<sub>2A</sub></td>
    <td>1,822</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>5-HT<sub>2B</sub></td>
    <td>143.7</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>5-HT<sub>7</sub></td>
    <td>2,850</td>
    <td>未知的</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>α<sub>1A</sub></td>
    <td>1,680</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>α<sub>1B</sub></td>
    <td>1,280</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>α<sub>1C</sub></td>
    <td>770</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>α<sub>1D</sub></td>
    <td>557</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>α<sub>2A</sub></td>
    <td>1.05</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>α<sub>2B</sub></td>
    <td>1.19</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>α<sub>2C</sub></td>
    <td>1.19</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>D<sub>2</sub></td>
    <td>339</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
   <tr>
    <td>D<sub>3</sub></td>
    <td>3,235</td>
    <td>拮抗剂</td>
    <td>人类</td>
    <td>无性繁殖</td>
   </tr>
  </tbody>
 </table><p></p></div></div><div id="par_14994942380212489"><h2 class="title">6 研究<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>育亨宾作为一种改善创伤后应激障碍患者暴露疗法效果的方法已被研究。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_33" class="kx_ref">[33]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_34" class="kx_ref">[34]</a></sup> </p><p>它也被作为勃起功能障碍的潜在治疗方法进行了研究，但是没有足够的证据来评价它的疗效。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_35" class="kx_ref">[35]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_35" class="kx_ref">[35]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_36" class="kx_ref">[36]</a></sup> 在美国，未经美国食品和药物管理局批准，销售含有育亨宾的非处方药物作为勃起功能障碍的治疗是非法的。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_37" class="kx_ref">[37]</a></sup> 然而，经常被宣传为促进性功能的膳食补充剂中育亨宾的量与处方剂量的育亨宾重叠。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_38" class="kx_ref">[38]</a></sup> </p><p>育亨宾阻断突触前和突触后α2受体。由于阴茎海绵体中的大多数肾上腺素受体属于α1型，因此阻断突触后α2受体仅会导致轻微的阴茎海绵体平滑肌松弛。突触前α2受体的阻断促进了中枢和外周神经系统——海绵体——中几种神经递质的释放，如一氧化氮和去甲肾上腺素。海绵体中释放的一氧化氮是导致勃起过程的主要血管扩张剂，而去甲肾上腺素是通过刺激海绵体平滑肌上的α1受体的主要血管收缩剂。然而，在生理条件下，一氧化氮会减弱去甲肾上腺素导致的的血管收缩。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_39" class="kx_ref">[39]</a></sup> </p></div></div><div id="par_14994942380212490"><h2 class="title">7 育亨宾的生物来源；可持续性<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>7.1 <span>Pausinystalia johimbe</span></h3><p></p><p>育亨宾的传统来源是非洲树育亨宾树P. johimbe的树皮。育亨宾树还有其他用途，但人们寻找它主要是为了它的树皮；实际上，收割树皮会杀死树木。树木密度相对较低(平均每公顷可采收树木约4棵)。对树皮类药物的高需求导致了这种树的过度开发。育亨宾树皮在当地市场交易，由于稀缺，经常和含有少量育亨宾的其他品种的树皮混在一起。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_40" class="kx_ref">[40]</a></sup> 育亨宾树这个物种正在濒临灭绝。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_40" class="kx_ref">[40]</a></sup> </p><p>大约在2000年，喀麦隆每年以大约100吨的速度向欧洲运送育亨宾树皮。大多数树皮是当地人非法收集的，他们在路边运送预先干燥的树皮，每公斤可获得150非洲法郎(约0.10美元)。实际上，他们把它和含有少量育亨宾的P. macroceras“假育亨宾”混为一谈。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_41" class="kx_ref">[41]</a></sup> </p><p></p><h3>7.2 <span>白雀麦Aspidosperma quebracho-blanco</span></h3><p></p><p>Aspidosperma quebracho-blanco是一种不相关的树，它的通用名是白坚木。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_42" class="kx_ref">[42]</a></sup> 它在南美洲中部的大部分地区都有发现，尤其是格兰查科，在那里它通常是冠层中的优势种。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_43" class="kx_ref">[43]</a></sup> 它是阿根廷分布最广的乔木树种之一。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_44" class="kx_ref">[44]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_45" class="kx_ref">[45]</a></sup> 传统上，它被用作燃料、木材和铁路枕木。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_45" class="kx_ref">[45]</a></sup> 尽管近年来牛牧场和大豆种植导致了相当大的栖息地丧失，<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_46" class="kx_ref">[46]</a></sup> 并仍有非法砍伐，但没有树皮短缺的报道。这棵树还没有被描述为濒危物种: Aspidosperma属的一些成员在国际自然保护联盟红色名单上。 但quebracho blanco物种不是其中之一。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_47" class="kx_ref">[47]</a></sup> </p><p>在其树皮中发现了一种生物碱，被命名为Quebrachine碱。1914年，两份科学论文声称Quebrachine碱在化学上与育亨宾相同。这是有争议的，这个问题长期以来一直是个疑问。然而，在1972年，Effler 和 Effler利用现代分析技术，包括质谱、紫外吸收、红外吸收和核磁共振，确定了Quebrachine碱和育亨宾是同一种物质。他们写道：</p><p>虽然这在1914年几乎是不可想象的...相同的生物碱在不同的植物中形成，最近的研究表明吲哚生物碱确实是这样。</p><p>一系列次级参考文献将“Quebrachine碱”作为育亨宾的同义词。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_48" class="kx_ref">[48]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_49" class="kx_ref">[49]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_50" class="kx_ref">[50]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_51" class="kx_ref">[51]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_52" class="kx_ref">[52]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_53" class="kx_ref">[53]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_54" class="kx_ref">[54]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_55" class="kx_ref">[55]</a></sup><sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_56" class="kx_ref">[56]</a></sup> </p><p>乔治·巴格尔·弗莱斯写道，严格来说，育亨宾应该被命名为quebrachine，因为它最初是从quebracho树中分离出来的，并在科学文献中首次被命名。然而，后来关于育亨宾的研究更广为人知，所以这个较新的名字被保留了下来。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_57" class="kx_ref">[57]</a></sup> </p><p></p><h3>7.3 <span>其他植物</span></h3><p></p><p>育亨宾也已从夹竹桃科的其他植物属中分离出来，包括骆驼蓬属(长春花属)、<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_58" class="kx_ref">[58]</a></sup> 萝芙木属、阿姆索尼亚属、山谷属和长春花属；马钱科(钩吻属和马钱子属)；大戟科(阿尔克霍纳属)。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_59" class="kx_ref">[59]</a></sup> </p></div></div><div id="par_14994942380212491"><h2 class="title">8 添加剂<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>世界反兴奋剂机构在2007有一个案例，据报道一名运动员在特定的体育赛事之前服用育亨宾，后来被检测出19-去甲雄酮（一种违禁物质）阳性，这是一种违禁物质。<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_59" class="kx_ref">[59]</a></sup> 然而，世界反兴奋剂组织尚未将育亨宾(可以通过能量饮料，<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_60" class="kx_ref">[60]</a></sup> 也可以以锻炼前补充剂或脂肪燃烧剂的形式进入体内<sup><a href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/d10091.htm#quote_61" class="kx_ref">[61]</a></sup>)列为禁用物质，也未证实使用育亨宾可以增加合成代谢类固醇的内源性水平，特别是19-去甲雄烯二酮和睾酮。</p></div></div></div></div><div id="references"><h2 class="title" id="par_references">参考文献</h2><ul class="references"><li id="quote_1"><span class="references-num">[1]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Yohimbine. (n.d.)". Collins English Dictionary – Complete and Unabridged. (1991, 1994, 1998, 2000, 2003). Retrieved 27 January 2015..</span></p></li><li id="quote_2"><span class="references-num">[2]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"21 CFR Sec. 522.2670 Yohimbine"..</span></p></li><li id="quote_3"><span class="references-num">[3]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Jeske AH, ed. (2013). Mosby's Dental Drug Reference - E-Book (11 ed.). Elsevier Health Sciences. ISBN 978-0323172264., Appendix H, e83;.</span></p></li><li id="quote_4"><span class="references-num">[4]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Holt S, Atkins RC, Krueger RJ, Sinatra ST, Taylor T (1999). The sexual revolution: natural and healthy alternatives to sex. ProMotion Pub. p. 105. ISBN 978-1579010409..</span></p></li><li id="quote_5"><span class="references-num">[5]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Oxford English Dictionary Online, article "Yohimbe", senses 1 and 2, respectively; Merriam-Webster Online, article "Yohimbe", first and second senses, respectively..</span></p></li><li id="quote_6"><span class="references-num">[6]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Sun J, Baker A, Chen P (September 2011). "Profiling the indole alkaloids in yohimbe bark with ultra-performance liquid chromatography coupled with ion mobility quadrupole time-of-flight mass spectrometry". Rapid Communications in Mass Spectrometry. 25 (18): 2591–602. doi:10.1002/rcm.5158. PMID 23657953..</span></p></li><li id="quote_7"><span class="references-num">[7]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA (2015). "Pharmaceutical quantities of yohimbine found in dietary supplements in the USA". Drug Testing and Analysis. 8 (3–4): 357–69. doi:10.1002/dta.1849. PMID 26391406..</span></p></li><li id="quote_8"><span class="references-num">[8]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">EFSA Panel on Food Additives and Nutrient Sources Added to Food (ANS) (2013). "Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille". EFSA Journal. 11 (7): 1–46. doi:10.2903/j.efsa.2013.3302..</span></p></li><li id="quote_9"><span class="references-num">[9]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Dr Betz was described as "a leading P. johimbe expert" by Cohen et al, 357. In 2018 he was appointed acting director of the Office of Dietary Supplements of the. NIH: "JOSEPH M. BETZ, PH.D., ACTING DIRECTOR, ODS". National Institutes of Health: Office of Dietary Supplements. Retrieved 28 January 2019..</span></p></li><li id="quote_10"><span class="references-num">[10]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Betz, 2010, 862..</span></p></li><li id="quote_11"><span class="references-num">[11]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Betz JM, White KD, der Marderosian AH (1995). "Gas chromatographic determination of yohimbine in commercial yohimbe products". Journal of AOAC International. 78 (5): 1189–94. PMID 7549534. Concentrations of yohimbine in the commercial products ranged from &lt; 0.1 to 489 ppm, compared with 7089 ppm in the authentic bark..</span></p></li><li id="quote_12"><span class="references-num">[12]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Zanolari B, Ndjoko K, Ioset JR, Marston A, Hostettmann K (2003). "Qualitative and quantitative determination of yohimbine in authentic yohimbe bark and in commercial aphrodisiacs by HPLC-UV-API/ MS methods". Phytochemical Analysis. 14 (4): 193–201. doi:10.1002/pca.699. PMID 12892413. Twenty commercial aphrodisiac preparations were analysed and the amount of yohimbine measured and expressed as the maximal dose per day suggested on product labels ranged from 1.32 to 23.16 mg..</span></p></li><li id="quote_13"><span class="references-num">[13]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Raman V, Avula B, Galal AM, Wang YH, Khan IA (January 2013). "Microscopic and UPLC-UV-MS analyses of authentic and commercial yohimbe (Pausinystalia johimbe) bark samples". Journal of Natural Medicines. 67 (1): 42–50. doi:10.1007/s11418-012-0642-2. PMID 22402817. Of 12 commercial samples tested, yohimbine was not detected in one; its presence in other samples was found to be in the range 0.1–0.91%..</span></p></li><li id="quote_14"><span class="references-num">[14]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Sun J, Chen P (March 2012). "Chromatographic fingerprint analysis of yohimbe bark and related dietary supplements using UHPLC/UV/MS". Journal of Pharmaceutical and Biomedical Analysis. 61: 142–9. doi:10.1016/j.jpba.2011.11.013. PMID 22221902. Wide variability was observed in fingerprints and yohimbine content among yohimbe dietary supplement samples. For most of the dietary supplements, the yohimbine content was not consistent with the label claims..</span></p></li><li id="quote_15"><span class="references-num">[15]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Badr JM (January 2013). "A validated high performance thin layer chromatography method for determination of yohimbine hydrochloride in pharmaceutical preparations". Pharmacognosy Magazine. 9 (33): 4–8. doi:10.4103/0973-1296.108124. PMC 3647393. PMID 23661986. Amount of yohimbine hydrochloride ranged from 2.3 to 5.2 mg/tablet or capsule in preparations containing the pure alkaloid, while it varied from zero to 1.5–1.8 mg/capsule in dietary supplements containing powdered yohimbe bark..</span></p></li><li id="quote_16"><span class="references-num">[16]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Cohen et al, 368. (Samples did not include other alkaloids characteristic of P. yohimbe.).</span></p></li><li id="quote_17"><span class="references-num">[17]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Paris R, Letouzey R (1960). "Répartition des alcaloïdes dans le Yohimbe (Pausinystalia yohimbe) (K. Schum.) ex Pierre". Journal d'Agriculture Traditionnelle et de Botanique Appliquée (in French). 7 (4–5): 256–258. doi:10.3406/jatba.1960.2608.CS1 maint: Unrecognized language (link).</span></p></li><li id="quote_18"><span class="references-num">[18]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">E.g. "Inspections, Compliance, Enforcement, and Criminal Investigations". US Food and Drug Administratiom. Retrieved 1 February 2019..</span></p></li><li id="quote_19"><span class="references-num">[19]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"21 U.S. Code § 321 - Definitions; generally". Legal Information Institute. Cornell Law School. Retrieved 1 February 2019..</span></p></li><li id="quote_20"><span class="references-num">[20]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Pausinystalia johimbe". Kew World Checklist of Selected Plant Families..</span></p></li><li id="quote_21"><span class="references-num">[21]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Year Book of the American Pharmaceutical Association. American Pharmaceutical Association. 1914. p. 564. Retrieved 2015-05-04..</span></p></li><li id="quote_22"><span class="references-num">[22]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Witkop B (1943). "Zur Konstitution des Yohimbins und seiner Abbauprodukte" [On the constitution of yohimbine and its breakdown products]. Justus Liebig's Annalen der Chemie (in German). 554 (1): 83–126. doi:10.1002/jlac.19435540108.CS1 maint: Unrecognized language (link).</span></p></li><li id="quote_23"><span class="references-num">[23]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">The Alkaloids: Chemistry and Pharmacology. 32. Academic Press. 1988. p. 564. ISBN 978-0-12-469532-0..</span></p></li><li id="quote_24"><span class="references-num">[24]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">van Tamelen E, Shamma M, Burgstahler A, Tamm R, Aldrich P (1958). "The Total Synthesis of Yohimbine". J. Am. Chem. Soc. 80 (18): 5006–5007. doi:10.1021/ja01551a062..</span></p></li><li id="quote_25"><span class="references-num">[25]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Herlé B, Wanner MJ, van Maarseveen JH, Hiemstra H (November 2011). "Total synthesis of (+)-yohimbine via an enantioselective organocatalytic Pictet-Spengler reaction". The Journal of Organic Chemistry. 76 (21): 8907–12. doi:10.1021/jo201657n. PMID 21950549..</span></p></li><li id="quote_26"><span class="references-num">[26]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, et al. (February 2000). "Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states". Synapse. 35 (2): 79–95. doi:10.1002/(SICI)1098-2396(200002)35:2&lt;79::AID-SYN1&gt;3.0.CO;2-X. PMID 10611634..</span></p></li><li id="quote_27"><span class="references-num">[27]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Yohimbine Test Ligand Search". PDSP Ki Database..</span></p></li><li id="quote_28"><span class="references-num">[28]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Arthur JM, Casañas SJ, Raymond JR (June 1993). "Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors". Biochemical Pharmacology. 45 (11): 2337–41. doi:10.1016/0006-2952(93)90208-E. PMID 8517875..</span></p></li><li id="quote_29"><span class="references-num">[29]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kaumann AJ (June 1983). "Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 323 (2): 149–54. doi:10.1007/BF00634263. PMID 6136920..</span></p></li><li id="quote_30"><span class="references-num">[30]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Baxter GS, Murphy OE, Blackburn TP (May 1994). "Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle". British Journal of Pharmacology. 112 (1): 323–31. doi:10.1111/j.1476-5381.1994.tb13072.x. PMC 1910288. PMID 8032658..</span></p></li><li id="quote_31"><span class="references-num">[31]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Yohimbine (PIM 567)". Inchem.org. Retrieved 2013-05-26..</span></p></li><li id="quote_32"><span class="references-num">[32]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Yohimbine". DrugBank. University of Alberta. Archived from the original on January 30, 2013. Retrieved 12 April 2014..</span></p></li><li id="quote_33"><span class="references-num">[33]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ (May 2015). "Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders". Review. Pharmacology &amp; Therapeutics. 149: 150–90. doi:10.1016/j.pharmthera.2014.12.004. PMC 4380664. PMID 25550231..</span></p></li><li id="quote_34"><span class="references-num">[34]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">McGuire JF, Lewin AB, Storch EA (August 2014). "Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder". Review. Expert Review of Neurotherapeutics. 14 (8): 893–910. doi:10.1586/14737175.2014.934677. PMC 4125602. PMID 24972729..</span></p></li><li id="quote_35"><span class="references-num">[35]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Yohimbe Supplement". National Center for Complementary and Integrative Health. February 2007. Retrieved 2017-08-28..</span></p></li><li id="quote_36"><span class="references-num">[36]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Andersson KE (September 2001). "Pharmacology of penile erection". Review. Pharmacological Reviews. 53 (3): 417–50. PMID 11546836..</span></p></li><li id="quote_37"><span class="references-num">[37]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"CFR - Code of Federal Regulations Title 21: Regulations on OTC products". U.S. Food and Drug Administration..</span></p></li><li id="quote_38"><span class="references-num">[38]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA (March 2016). "Pharmaceutical quantities of yohimbine found in dietary supplements in the USA". primary. Drug Testing and Analysis. 8 (3–4): 357–69. doi:10.1002/dta.1849. PMID 26391406..</span></p></li><li id="quote_39"><span class="references-num">[39]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Saenz de Tejada I, Kim NN, Goldstein I, Traish AM (March 2000). "Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum". Review. International Journal of Impotence Research. 12 Suppl 1: S20–25. doi:10.1038/sj.ijir.3900500. PMID 10845761..</span></p></li><li id="quote_40"><span class="references-num">[40]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Jiofack Tafokou RB (2012). "Pausinystalia johimbe". In Lemmens RH, Louppe D, Oteng-Amoako AA. Timbers 2 of Plant Resources of Tropical Africa. 7. Wageningen, Ne: PROTA Foundation. pp. 516–519. ISBN 978-9290814955..</span></p></li><li id="quote_41"><span class="references-num">[41]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Sunderland TC, Ngo-Mpeck M, Tchoundjeu Z, Laird SA (2002). "Yohimbe (Pausinstalia johimbe)". In Shanley P, Pierce AR, Laird SA, Guillén A. Tapping the Green Market: Certification &amp; Management of Non-Timber Forest Products. Earthscan Publications Ltd. pp. 215–224. ISBN 978-1853838712..</span></p></li><li id="quote_42"><span class="references-num">[42]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Quebracho" is formed from the Spanish words for "axe breaker'..</span></p></li><li id="quote_43"><span class="references-num">[43]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bucher, E.H. (2012). "Chaco and Caatinga — South American Arid Savannas, Woodlands and Thickets". In Huntley, B.J.; Walker, B.H. Ecology of Tropical Savannas. Ecological Studies. 42. Springer Science and Business. Media. pp. 54–57. ISBN 978-3642687860..</span></p></li><li id="quote_44"><span class="references-num">[44]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Nombre científico: Aspidosperma quebracho-blanco". Herbario Digital (in Spanish). CONICET. Retrieved 12 January 2019.CS1 maint: Unrecognized language (link).</span></p></li><li id="quote_45"><span class="references-num">[45]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Moglia JG, López CR (2001). "Variabilidad radial de algunos caracteres anatómicos de Aspidosperma quebracho blanco" [Radial variability of some anatomical characters of Aspidosperma white quebracho]. Bosque (in Spanish). 22 (2): 4. doi:10.4206/bosque.2001.v22n2-01. ISSN 0304-8799.CS1 maint: Unrecognized language (link).</span></p></li><li id="quote_46"><span class="references-num">[46]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kent RB (2006). Latin America: Regions and People. Texts in regional geography. Guilford Press. p. 151. ISBN 978-1572309098..</span></p></li><li id="quote_47"><span class="references-num">[47]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"The IUCN Red List of Threatened Species". Retrieved 12 January 2019..</span></p></li><li id="quote_48"><span class="references-num">[48]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Abel, G.; et al. (2012). Adverse Effects of Herbal Drugs. 3. Springer Science &amp; Business Media. ISBN 978-3642603679..</span></p></li><li id="quote_49"><span class="references-num">[49]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bosker G (1995). Emergency Medicine Therapeutics (2 ed.). Mosby, Incorporated. p. 342. ISBN 978-0815109921..</span></p></li><li id="quote_50"><span class="references-num">[50]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Philippsborn H (2006). Elsevier's Dictionary of Vitamins and Pharmacochemistry. Elsevier. p. 599. ISBN 978-0080488790..</span></p></li><li id="quote_51"><span class="references-num">[51]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Staff (1983). Food and Drug Administration Consumer. U.S. Department of Health, Education, and Welfare, Public Health Service, Food and Drug Administration. p. 10..</span></p></li><li id="quote_52"><span class="references-num">[52]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lewis RA, Hawley GG (2016). Larrañaga MD, Lewis RJ, Lewis R, eds. Hawley's Condensed Chemical Dictionary. John Wiley &amp; Sons. p. 1438. ISBN 978-1118135150..</span></p></li><li id="quote_53"><span class="references-num">[53]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Jeske AH, ed. (2013). Mosby's Dental Drug Reference - E-Book (11 ed.). Elsevier Health Sciences. pp. Appendix H, e83. ISBN 978-0323172264..</span></p></li><li id="quote_54"><span class="references-num">[54]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Manske R, Meurant G (1965). The Alkaloids: Chemistry and Physiology. 8. Academic Press. p. 696. ISBN 978-0080865324..</span></p></li><li id="quote_55"><span class="references-num">[55]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Riviere JE, Papich MG, eds. (2013). Veterinary Pharmacology and Therapeutics (9 ed.). John Wiley &amp; Sons. p. 353. ISBN 978-1118685907..</span></p></li><li id="quote_56"><span class="references-num">[56]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Yeung AY, Foster S (2003). Encyclopedia of Common Natural Ingredients: Used in Food, Drugs, and Cosmetics (2 ed.). Wiley. p. 431. ISBN 978-0471471288...</span></p></li><li id="quote_57"><span class="references-num">[57]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Barger G, Field E (1915). "Yohimbine (Quebrachine)". Journal of the Chemical Society, Transactions. 107: 1025. doi:10.1039/CT9150701025..</span></p></li><li id="quote_58"><span class="references-num">[58]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hammouda Y, Janot MM, Le Men J (May 1956). "[Presence of yohimbine (quebrachin) in the roots of Madagascar periwinkle, Lochnera lancea]". Annales Pharmaceutiques Francaises (in French). 14 (5): 341–4. PMID 13373134.CS1 maint: Unrecognized language (link).</span></p></li><li id="quote_59"><span class="references-num">[59]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Betz JM (2010). "Yohimbe". In Coates PM, Betz JM, Blackman MR, Cragg GM, Levine M, Moss J, White JD. Encyclopedia of Dietary Supplements (2nd ed.). New York and London: Informa Healthcare. p. 861–3. ISBN 9781439819289..</span></p></li><li id="quote_60"><span class="references-num">[60]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">U.S. Anti-Doping Agency Supplement Guide, p. 28..</span></p></li><li id="quote_61"><span class="references-num">[61]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Doping substances in dietary supplements.</span></p></li></ul></div><div class="read-num">阅读 <!-- -->1902</div></div><div class="right-side" id="rightSide"><div class="side" id="lemma-side"><div class="side-title">版本记录</div><ul class="side-lst"><li><p class="side-lst-txt">暂无</p></li></ul><div class="user-card userCard"></div></div><div class="side"><div class="side-event"></div></div></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://web.archive.org/web/20221028215451/https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="https://web.archive.org/web/20221028215451/http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="https://web.archive.org/web/20221028215451/http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://web.archive.org/web/20221028215451/https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"10091","versionId":"54115707041931777","title":"育亨宾","subtitle":"","abstracts":{"paragraphId":"52079316648904704","title":"摘要","versionId":"54115707041931778","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p>育亨宾(/joʊˈhɪmbiːn/)，<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> 是一种吲哚醌类生物碱，来源于非洲育亨宾树和名字与其无关的南美洲白树的树皮。育亨宾是一种α-2肾上腺素受体阻断剂，已被用于多种研究项目。育亨宾是一种兽药，用于让狗和鹿从镇静中恢复。虽然育亨宾在一些哺乳动物身上使用时有春药的作用，但在人类身上却没有此类功效。它已被用作治疗勃起功能障碍，但据报道其临床作用不大，并且已被PDE5抑制剂类药物所取代。据称，育亨宾树提取物的物质已经作为膳食补充剂进行销售，但是它们含有的育亨宾量是非常不确定的（如果有的话）；没有公开的科学证据支持其疗效。</p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028215451/https://img03.sogoucdn.com/app/a/200698/360_360_20200908155022-835215598.jpg?width=227&height=174&titlename=&w=360&h=360","url":"https://web.archive.org/web/20221028215451/https://img03.sogoucdn.com/app/a/200698/360_360_20200908155022-835215598.jpg","rw":360,"rh":360,"title":"","alt":null,"width":227,"height":174}],"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"14994942346658068","title":"基本信息","versionId":"54115707041931779","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":3,"content":"","pics":null,"card":{"cardItems":[{"key":"性质","value":"白色粉末，味微苦"}]},"references":[],"versionCount":0},"categories":[{"id":3,"name":"化学","parents":[]}],"creator":{"uid":35191347,"name":"脏兮兮","pic":"https://web.archive.org/web/20221028215451/https://cache.soso.com/qlogo/g?b=oidb&k=KSL8IVFMTCNN3hJoFibhDLA&s=100&t=1555765973","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":"","phoneNo":null,"editable":true,"partnerId":144,"partnerIdCreateTime":1595844881,"partnerIdPoped":true},"createTime":1571038201,"editor":{"uid":81910391,"name":"是福不是祸","pic":"https://web.archive.org/web/20221028215451/https://cache.soso.com/qlogo/g?b=oidb&k=6iaUd8ybMyWyTRyUPWibRsLg&s=100&t=1566664174","introduction":"全幼儿园最可爱的小朋友","educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":"","phoneNo":null,"editable":true,"partnerId":236,"partnerIdCreateTime":1596529271,"partnerIdPoped":true},"editTime":1598337691,"state":1,"versionCount":2,"upNum":0,"downNum":0,"pics":[{"originalUrl":"https://web.archive.org/web/20221028215451/https://img03.sogoucdn.com/app/a/200698/360_360_20200908155022-835215598.jpg?width=227&height=174&titlename=&w=360&h=360","url":"https://web.archive.org/web/20221028215451/https://img03.sogoucdn.com/app/a/200698/360_360_20200908155022-835215598.jpg","rw":360,"rh":360,"title":"","alt":null,"width":227,"height":174}],"catalogs":[{"level":1,"title":"使用","paragraphId":"14994942346658069","subCatalogs":null},{"level":1,"title":"育亨宾和育亨宾树","paragraphId":"14994942346658070","subCatalogs":[{"level":2,"title":"混淆","paragraphId":"14994942346658070","subCatalogs":null},{"level":2,"title":"对性功能的影响","paragraphId":"14994942346658070","subCatalogs":null},{"level":2,"title":"育亨宾和膳食补充剂","paragraphId":"14994942346658070","subCatalogs":null}]},{"level":1,"title":"毒性","paragraphId":"14994942363435268","subCatalogs":null},{"level":1,"title":"提取物和化学性质","paragraphId":"14994942363435269","subCatalogs":null},{"level":1,"title":"药理学","paragraphId":"14994942363435270","subCatalogs":null},{"level":1,"title":"研究","paragraphId":"14994942380212489","subCatalogs":null},{"level":1,"title":"育亨宾的生物来源；可持续性","paragraphId":"14994942380212490","subCatalogs":[{"level":2,"title":"<i>Pausinystalia johimbe</i>","paragraphId":"14994942380212490","subCatalogs":null},{"level":2,"title":"<i>白雀麦Aspidosperma quebracho-blanco</i>","paragraphId":"14994942380212490","subCatalogs":null},{"level":2,"title":"其他植物","paragraphId":"14994942380212490","subCatalogs":null}]},{"level":1,"title":"添加剂","paragraphId":"14994942380212491","subCatalogs":null},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"14994942346658069","title":"使用","versionId":"54115707041931780","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>育亨宾是一种兽药，用于让狗和鹿从赛拉嗪的镇静作用中恢复。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 它被用作研究用试剂。在美国，它是针对男性勃起功能障碍的处方药，但现在很少使用了。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994942346658070","title":"育亨宾和育亨宾树","versionId":"54115707041931781","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3>混淆</h3></p><p>育亨宾不应该和育亨宾树混淆，<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup> 但经常发生此类混淆。<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> </p><p>育亨宾（Yohimbe）是育亨宾树树种（P. johimbe）的通用英文名称，也是由其树皮制成的药物制剂的名称，作为壮阳药出售。<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup> 相比之下，育亨宾（yohimbine）是一种纯生物碱，可以从育亨宾树皮中分离出来。</p><p>育亨宾只是从育亨宾树皮中分离出的55种吲哚生物碱之一；<sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup> 并且，尽管它被描述为其中最活跃的组分，<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> 但它仅占总生物碱含量的15%。 其他生物碱包括萝芙木碱、棒状碱和阿吉马利辛； 树皮中还含有其他组分未知的非生物碱。</p><p>因此，育亨宾是一种复杂的混合物，对它的研究远不如育亨宾这种纯化合物彻底。 药用级育亨宾通常以盐酸盐的形式出现，<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup> 更易溶解。</p><p><h3>对性功能的影响</h3></p><p><strong>历史、研究和文献</strong></p><p>育亨宾在民间医学中被用作壮阳药。根据2010年美国国立卫生研究院的Joseph M. Betz撰写的百科全书文章，1900年，它引起了德国科学界的兴趣，最初的一份报告称育亨宾对动物和人类有很强的壮阳作用。 人们的注意力很快从这种植物转移到它的活性成分上，尤其是是育亨宾。 <sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup> </p><p>也许正是由于这一趋势，在文献中找不到关于育亨宾树皮或其提取物对人类性行为影响的研究报告...因此，任何关于使用育亨宾树皮提高性能力的讨论都是以民间传说开始和结束的。</p><p>相比之下，关于育亨宾这个物质的文献“相当丰富”。</p><p>育亨宾的后续研究虽然证实它在动物身上（包括老鼠、狗和金仓鼠）有壮阳药的作用，但在人类身上却没有。但是根据Betz的研究，实验</p><p>表明即使用在性疲惫的大鼠身上也会增加性欲，因为它对大脑蓝斑中发现的中枢α2-肾上腺素受体起作用。对大脑肾上腺素受体的阻断似乎逆转了调节阴茎勃起和维持消肿的中枢负反馈机制...育亨宾不会增加人类临床试验中的性欲。来自人类和动物临床研究的综合证据表明，育亨宾在刺激人类性行为方面的效果远远不如大鼠。对这一发现的一个可能的解释是人类的性行为存在着比老鼠更复杂的多重抑制控制，也就是说，人类对性的认知远比在动物身上观察到的基本基于本能的功能更重要。</p><p><strong>临床疗效</strong></p><p>育亨宾已经被用来治疗女性性功能障碍，但是很少有临床试验的报道，而且这些试验并没有显示它优于安慰剂。<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup> 关于男性勃起功能障碍的治疗，Tam等人(2001年)的一篇综述文章总结道：</p><p>尽管它耐受性好且安全，即使大大超出了可能的治疗范围，但很明显，在一般勃起功能障碍人群中作为单一疗法的疗效可能不大。</p><p>根据贝茨(2010年)的说法，</p><p>现代的共识似乎是纯化合物育亨宾对某些男性的某些轻度勃起功能障碍有效，但不能作为壮阳药。</p><p>安德森在2011年的一篇综述中说：</p><p>育亨宾对不同类型的勃起功能障碍患者的效果已经在几个对照试验中被研究，但效果并不明显...不能排除口服育亨宾对某些勃起功能障碍患者可能有有益的效果。然而，由于结果相互矛盾，目前在大多数勃起功能障碍治疗指南中并不建议这样做。</p><p>育亨宾已经被西地那非(如伟哥)和其他PDE5抑制剂药物所取代。处方药现在很少见，大多数美国制药商已经停止生产处方胶囊和片剂。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> </p><p><h3>育亨宾和膳食补充剂</h3></p><p>在美国，“育亨宾”制剂作为增强性欲、减肥和健美的辅助食品出售；但是“几乎没有关于育亨宾的公开研究支持这些或任何其他说法”。 通常，这些产品明确声称含有育亨宾。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> </p><p>科恩等人发现，在美国实体店销售的品牌样品中，育亨宾的含量变化很大，有时甚至根本不含育亨宾。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> 标签声明往往具有误导性。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> 其他实验室也报告了在美国，其他国家和互联网上销售的产品的类似结果。<sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup><sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup><sup><a href=\"#quote_13\" class=\"kx_ref\">[13]</a></sup><sup><a href=\"#quote_14\" class=\"kx_ref\">[14]</a></sup><sup><a href=\"#quote_15\" class=\"kx_ref\">[15]</a></sup> 一项研究发现，许多品牌的“育亨宾”可能最初并不是来自于育亨宾树。<sup><a href=\"#quote_16\" class=\"kx_ref\">[16]</a></sup> 根据另一个消息来源，在西非（育亨宾树生长的地方）出售育亨宾的市场上，育亨宾经常掺杂其他种类的育亨宾属类树含有的少量育亨宾。 即使在真正的育亨宾树皮中发现的生物碱的量也有很大差异，这取决于树皮的来源（根，茎，枝，高度等）。<sup><a href=\"#quote_17\" class=\"kx_ref\">[17]</a></sup> </p><p>一些在场外销售的品牌被发现每剂育亨宾的含量超过标准药物剂量；<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> 然而，在美国，药品受到严格的药品监管制度的制约。未经食品和药物管理局许可，在州际贸易中引入或运送“药物”是非法的。美国食品和药物管理局声称，一些含育亨宾的产品是“药物”，因为它们的推广显示表示“它们旨在用于治疗、缓解、治疗或预防疾病”:《美国法典》第21篇第321(g)(1)(B)节。<sup><a href=\"#quote_18\" class=\"kx_ref\">[18]</a></sup> 然而，法律立场并不完全明确，<sup><a href=\"#quote_19\" class=\"kx_ref\">[19]</a></sup> 截至2019年2月1日，似乎没有任何成功起诉的记录。</p><p>由于缺乏育亨宾的可靠科学数据，欧洲食品安全管理局食品添加剂小组认定，欧洲食品安全局食品添加剂专家组确定无法就其安全性做出结论，也无法建立一个基于健康准则的指导值。他们写道：</p><p>总体而言，缺失信息包括育亨宾树皮及其制剂的组成和规格的定量数据，用于食品和食品补充剂，包括育亨宾以外的其他生物碱，育亨宾树皮提取物中活性成分的生物利用度数据，育亨宾树皮和育亨宾树皮主要生物碱的具体制剂的毒性数据，特别是亚慢性毒性、遗传毒性和生殖毒性数据。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994942363435268","title":"毒性","versionId":"54115707041931782","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>根据剂量的不同，育亨宾可以增加或降低全身血压(血管收缩或血管舒张)。因为育亨宾对α2受体的亲和力最高，所以小剂量的育亨宾可以通过引起相对选择性的α2阻滞来增加血压。尽管亲和力较低，育亨宾也与α1受体相互作用；因此，在较高剂量下，可能会出现α1阻滞，并超过α2阻滞的效果，导致潜在的血压下降隐患。 口服高剂量育亨宾可能会产生许多副作用，如心率加快、刺激过度、血压异常、冷汗和失眠。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994942363435269","title":"提取物和化学性质","versionId":"54115707041931783","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>育亨宾树(Pausinystalia johimbe)是一种生长在西非和中非的树；<sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup>育亨宾最初是由阿道夫·斯皮格尔于1896年从育亨宾树皮中提取的。<sup><a href=\"#quote_21\" class=\"kx_ref\">[21]</a></sup> (事实上，它早些时候就已经从南美的白树树皮中分离出来，并被命名为白坚木碱，但这一点被忽略了)。1943年，Witkop提出育亨宾的正确结构。<sup><a href=\"#quote_22\" class=\"kx_ref\">[22]</a></sup> 十五年后，尤金·范·塔梅伦(Eugene van Tamelen)领导的团队利用23步合成法首次实现育亨宾全合成。<sup><a href=\"#quote_23\" class=\"kx_ref\">[23]</a></sup><sup><a href=\"#quote_24\" class=\"kx_ref\">[24]</a></sup><sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994942363435270","title":"药理学","versionId":"54115707041931784","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>育亨宾对α2肾上腺素能受体具有高亲和力，对α1受体、5-HT1A、5-HT1B、5-HT1D、5-HT1F、5-HT2B和多巴胺D2受体具有中等亲和力，对5-HT1E、5-HT2A、5-HT5A、5-HT7和多巴胺D3受体具有弱亲和力。<sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup><sup><a href=\"#quote_27\" class=\"kx_ref\">[27]</a></sup> 它在α1肾上腺素、α2肾上腺素、5-HT1B、5-HT1D、5-HT2A、5-HT2B和多巴胺D2上表现为拮抗剂，在5-HT1A上表现为部分激动剂。<sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup><sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup><sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup><sup><a href=\"#quote_30\" class=\"kx_ref\">[30]</a></sup> 高浓度的育亨宾与血清素和多巴胺受体相互作用。<sup><a href=\"#quote_31\" class=\"kx_ref\">[31]</a></sup> </p><p>\n <table class=\"wikitable sortable\">\n  <caption>\n   药理概况\n  </caption>\n  <tbody>\n   <tr>\n    <th>分子靶</th>\n    <th>亲合力<br>(千纳摩尔)<sup><a href=\"#quote_27\" class=\"kx_ref\">[27]</a></sup></th>\n    <th>药理作用<br><sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup><sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup><sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup><sup><a href=\"#quote_30\" class=\"kx_ref\">[30]</a></sup><sup><a href=\"#quote_32\" class=\"kx_ref\">[32]</a></sup></th>\n    <th>种类</th>\n    <th>来源</th>\n   </tr>\n   <tr>\n    <td>SERT</td>\n    <td>1,000</td>\n    <td>抑制剂</td>\n    <td>人类</td>\n    <td>额叶皮层</td>\n   </tr>\n   <tr>\n    <td>5-HT<sub>1A</sub></td>\n    <td>346</td>\n    <td>部分激动剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>5-HT<sub>1B</sub></td>\n    <td>19.9</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>5-HT<sub>1D</sub></td>\n    <td>44.3</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>5-HT<sub>1E</sub></td>\n    <td>1,264</td>\n    <td>未知的</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>5-HT<sub>1F</sub></td>\n    <td>91.6</td>\n    <td>未知的</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>5-HT<sub>2A</sub></td>\n    <td>1,822</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>5-HT<sub>2B</sub></td>\n    <td>143.7</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>5-HT<sub>7</sub></td>\n    <td>2,850</td>\n    <td>未知的</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>α<sub>1A</sub></td>\n    <td>1,680</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>α<sub>1B</sub></td>\n    <td>1,280</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>α<sub>1C</sub></td>\n    <td>770</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>α<sub>1D</sub></td>\n    <td>557</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>α<sub>2A</sub></td>\n    <td>1.05</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>α<sub>2B</sub></td>\n    <td>1.19</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>α<sub>2C</sub></td>\n    <td>1.19</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>D<sub>2</sub></td>\n    <td>339</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n   <tr>\n    <td>D<sub>3</sub></td>\n    <td>3,235</td>\n    <td>拮抗剂</td>\n    <td>人类</td>\n    <td>无性繁殖</td>\n   </tr>\n  </tbody>\n </table></p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994942380212489","title":"研究","versionId":"54115707041931785","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>育亨宾作为一种改善创伤后应激障碍患者暴露疗法效果的方法已被研究。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup><sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup> </p><p>它也被作为勃起功能障碍的潜在治疗方法进行了研究，但是没有足够的证据来评价它的疗效。<sup><a href=\"#quote_35\" class=\"kx_ref\">[35]</a></sup><sup><a href=\"#quote_35\" class=\"kx_ref\">[35]</a></sup><sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup> 在美国，未经美国食品和药物管理局批准，销售含有育亨宾的非处方药物作为勃起功能障碍的治疗是非法的。<sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup> 然而，经常被宣传为促进性功能的膳食补充剂中育亨宾的量与处方剂量的育亨宾重叠。<sup><a href=\"#quote_38\" class=\"kx_ref\">[38]</a></sup> </p><p>育亨宾阻断突触前和突触后α2受体。由于阴茎海绵体中的大多数肾上腺素受体属于α1型，因此阻断突触后α2受体仅会导致轻微的阴茎海绵体平滑肌松弛。突触前α2受体的阻断促进了中枢和外周神经系统——海绵体——中几种神经递质的释放，如一氧化氮和去甲肾上腺素。海绵体中释放的一氧化氮是导致勃起过程的主要血管扩张剂，而去甲肾上腺素是通过刺激海绵体平滑肌上的α1受体的主要血管收缩剂。然而，在生理条件下，一氧化氮会减弱去甲肾上腺素导致的的血管收缩。<sup><a href=\"#quote_39\" class=\"kx_ref\">[39]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994942380212490","title":"育亨宾的生物来源；可持续性","versionId":"54115707041931786","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3><i>Pausinystalia johimbe</i></h3></p><p>育亨宾的传统来源是非洲树育亨宾树P. johimbe的树皮。育亨宾树还有其他用途，但人们寻找它主要是为了它的树皮；实际上，收割树皮会杀死树木。树木密度相对较低(平均每公顷可采收树木约4棵)。对树皮类药物的高需求导致了这种树的过度开发。育亨宾树皮在当地市场交易，由于稀缺，经常和含有少量育亨宾的其他品种的树皮混在一起。<sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup> 育亨宾树这个物种正在濒临灭绝。<sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup> </p><p>大约在2000年，喀麦隆每年以大约100吨的速度向欧洲运送育亨宾树皮。大多数树皮是当地人非法收集的，他们在路边运送预先干燥的树皮，每公斤可获得150非洲法郎(约0.10美元)。实际上，他们把它和含有少量育亨宾的P. macroceras“假育亨宾”混为一谈。<sup><a href=\"#quote_41\" class=\"kx_ref\">[41]</a></sup> </p><p><h3><i>白雀麦Aspidosperma quebracho-blanco</i></h3></p><p>Aspidosperma quebracho-blanco是一种不相关的树，它的通用名是白坚木。<sup><a href=\"#quote_42\" class=\"kx_ref\">[42]</a></sup> 它在南美洲中部的大部分地区都有发现，尤其是格兰查科，在那里它通常是冠层中的优势种。<sup><a href=\"#quote_43\" class=\"kx_ref\">[43]</a></sup> 它是阿根廷分布最广的乔木树种之一。<sup><a href=\"#quote_44\" class=\"kx_ref\">[44]</a></sup><sup><a href=\"#quote_45\" class=\"kx_ref\">[45]</a></sup> 传统上，它被用作燃料、木材和铁路枕木。<sup><a href=\"#quote_45\" class=\"kx_ref\">[45]</a></sup> 尽管近年来牛牧场和大豆种植导致了相当大的栖息地丧失，<sup><a href=\"#quote_46\" class=\"kx_ref\">[46]</a></sup> 并仍有非法砍伐，但没有树皮短缺的报道。这棵树还没有被描述为濒危物种: Aspidosperma属的一些成员在国际自然保护联盟红色名单上。 但quebracho blanco物种不是其中之一。<sup><a href=\"#quote_47\" class=\"kx_ref\">[47]</a></sup> </p><p>在其树皮中发现了一种生物碱，被命名为Quebrachine碱。1914年，两份科学论文声称Quebrachine碱在化学上与育亨宾相同。这是有争议的，这个问题长期以来一直是个疑问。然而，在1972年，Effler 和 Effler利用现代分析技术，包括质谱、紫外吸收、红外吸收和核磁共振，确定了Quebrachine碱和育亨宾是同一种物质。他们写道：</p><p>虽然这在1914年几乎是不可想象的...相同的生物碱在不同的植物中形成，最近的研究表明吲哚生物碱确实是这样。</p><p>一系列次级参考文献将“Quebrachine碱”作为育亨宾的同义词。<sup><a href=\"#quote_48\" class=\"kx_ref\">[48]</a></sup><sup><a href=\"#quote_49\" class=\"kx_ref\">[49]</a></sup><sup><a href=\"#quote_50\" class=\"kx_ref\">[50]</a></sup><sup><a href=\"#quote_51\" class=\"kx_ref\">[51]</a></sup><sup><a href=\"#quote_52\" class=\"kx_ref\">[52]</a></sup><sup><a href=\"#quote_53\" class=\"kx_ref\">[53]</a></sup><sup><a href=\"#quote_54\" class=\"kx_ref\">[54]</a></sup><sup><a href=\"#quote_55\" class=\"kx_ref\">[55]</a></sup><sup><a href=\"#quote_56\" class=\"kx_ref\">[56]</a></sup> </p><p>乔治·巴格尔·弗莱斯写道，严格来说，育亨宾应该被命名为quebrachine，因为它最初是从quebracho树中分离出来的，并在科学文献中首次被命名。然而，后来关于育亨宾的研究更广为人知，所以这个较新的名字被保留了下来。<sup><a href=\"#quote_57\" class=\"kx_ref\">[57]</a></sup> </p><p><h3>其他植物</h3></p><p>育亨宾也已从夹竹桃科的其他植物属中分离出来，包括骆驼蓬属(长春花属)、<sup><a href=\"#quote_58\" class=\"kx_ref\">[58]</a></sup> 萝芙木属、阿姆索尼亚属、山谷属和长春花属；马钱科(钩吻属和马钱子属)；大戟科(阿尔克霍纳属)。<sup><a href=\"#quote_59\" class=\"kx_ref\">[59]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994942380212491","title":"添加剂","versionId":"54115707041931787","lemmaId":10091,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599551474,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>世界反兴奋剂机构在2007有一个案例，据报道一名运动员在特定的体育赛事之前服用育亨宾，后来被检测出19-去甲雄酮（一种违禁物质）阳性，这是一种违禁物质。<sup><a href=\"#quote_59\" class=\"kx_ref\">[59]</a></sup> 然而，世界反兴奋剂组织尚未将育亨宾(可以通过能量饮料，<sup><a href=\"#quote_60\" class=\"kx_ref\">[60]</a></sup> 也可以以锻炼前补充剂或脂肪燃烧剂的形式进入体内<sup><a href=\"#quote_61\" class=\"kx_ref\">[61]</a></sup>)列为禁用物质，也未证实使用育亨宾可以增加合成代谢类固醇的内源性水平，特别是19-去甲雄烯二酮和睾酮。</p>","pics":null,"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"book","title":"\"Yohimbine. (n.d.)\". Collins English Dictionary – Complete and Unabridged. (1991, 1994, 1998, 2000, 2003). Retrieved 27 January 2015.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":2,"type":"book","title":"\"21 CFR Sec. 522.2670 Yohimbine\".","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":3,"type":"book","title":"Jeske AH, ed. (2013). Mosby's Dental Drug Reference - E-Book (11 ed.). Elsevier Health Sciences. ISBN 978-0323172264., Appendix H, e83;","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":4,"type":"book","title":"Holt S, Atkins RC, Krueger RJ, Sinatra ST, Taylor T (1999). The sexual revolution: natural and healthy alternatives to sex. ProMotion Pub. p. 105. ISBN 978-1579010409.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":5,"type":"book","title":"Oxford English Dictionary Online, article \"Yohimbe\", senses 1 and 2, respectively; Merriam-Webster Online, article \"Yohimbe\", first and second senses, respectively.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":6,"type":"book","title":"Sun J, Baker A, Chen P (September 2011). \"Profiling the indole alkaloids in yohimbe bark with ultra-performance liquid chromatography coupled with ion mobility quadrupole time-of-flight mass spectrometry\". Rapid Communications in Mass Spectrometry. 25 (18): 2591–602. doi:10.1002/rcm.5158. PMID 23657953.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":7,"type":"book","title":"Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA (2015). \"Pharmaceutical quantities of yohimbine found in dietary supplements in the USA\". Drug Testing and Analysis. 8 (3–4): 357–69. doi:10.1002/dta.1849. PMID 26391406.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":8,"type":"book","title":"EFSA Panel on Food Additives and Nutrient Sources Added to Food (ANS) (2013). \"Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille\". EFSA Journal. 11 (7): 1–46. doi:10.2903/j.efsa.2013.3302.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":9,"type":"book","title":"Dr Betz was described as \"a leading P. johimbe expert\" by Cohen et al, 357. In 2018 he was appointed acting director of the Office of Dietary Supplements of the. NIH: \"JOSEPH M. BETZ, PH.D., ACTING DIRECTOR, ODS\". National Institutes of Health: Office of Dietary Supplements. Retrieved 28 January 2019.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":10,"type":"book","title":"Betz, 2010, 862.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":11,"type":"book","title":"Betz JM, White KD, der Marderosian AH (1995). \"Gas chromatographic determination of yohimbine in commercial yohimbe products\". Journal of AOAC International. 78 (5): 1189–94. PMID 7549534. Concentrations of yohimbine in the commercial products ranged from < 0.1 to 489 ppm, compared with 7089 ppm in the authentic bark.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":12,"type":"book","title":"Zanolari B, Ndjoko K, Ioset JR, Marston A, Hostettmann K (2003). \"Qualitative and quantitative determination of yohimbine in authentic yohimbe bark and in commercial aphrodisiacs by HPLC-UV-API/ MS methods\". Phytochemical Analysis. 14 (4): 193–201. doi:10.1002/pca.699. PMID 12892413. Twenty commercial aphrodisiac preparations were analysed and the amount of yohimbine measured and expressed as the maximal dose per day suggested on product labels ranged from 1.32 to 23.16 mg.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":13,"type":"book","title":"Raman V, Avula B, Galal AM, Wang YH, Khan IA (January 2013). \"Microscopic and UPLC-UV-MS analyses of authentic and commercial yohimbe (Pausinystalia johimbe) bark samples\". Journal of Natural Medicines. 67 (1): 42–50. doi:10.1007/s11418-012-0642-2. PMID 22402817. Of 12 commercial samples tested, yohimbine was not detected in one; its presence in other samples was found to be in the range 0.1–0.91%.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":14,"type":"book","title":"Sun J, Chen P (March 2012). \"Chromatographic fingerprint analysis of yohimbe bark and related dietary supplements using UHPLC/UV/MS\". Journal of Pharmaceutical and Biomedical Analysis. 61: 142–9. doi:10.1016/j.jpba.2011.11.013. PMID 22221902. Wide variability was observed in fingerprints and yohimbine content among yohimbe dietary supplement samples. For most of the dietary supplements, the yohimbine content was not consistent with the label claims.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":15,"type":"book","title":"Badr JM (January 2013). \"A validated high performance thin layer chromatography method for determination of yohimbine hydrochloride in pharmaceutical preparations\". Pharmacognosy Magazine. 9 (33): 4–8. doi:10.4103/0973-1296.108124. PMC 3647393. PMID 23661986. Amount of yohimbine hydrochloride ranged from 2.3 to 5.2 mg/tablet or capsule in preparations containing the pure alkaloid, while it varied from zero to 1.5–1.8 mg/capsule in dietary supplements containing powdered yohimbe bark.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":16,"type":"book","title":"Cohen et al, 368. (Samples did not include other alkaloids characteristic of P. yohimbe.)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":17,"type":"book","title":"Paris R, Letouzey R (1960). \"Répartition des alcaloïdes dans le Yohimbe (Pausinystalia yohimbe) (K. Schum.) ex Pierre\". Journal d'Agriculture Traditionnelle et de Botanique Appliquée (in French). 7 (4–5): 256–258. doi:10.3406/jatba.1960.2608.CS1 maint: Unrecognized language (link)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":18,"type":"book","title":"E.g. \"Inspections, Compliance, Enforcement, and Criminal Investigations\". US Food and Drug Administratiom. Retrieved 1 February 2019.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":19,"type":"book","title":"\"21 U.S. Code § 321 - Definitions; generally\". Legal Information Institute. Cornell Law School. Retrieved 1 February 2019.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":20,"type":"book","title":"\"Pausinystalia johimbe\". Kew World Checklist of Selected Plant Families.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":21,"type":"book","title":"Year Book of the American Pharmaceutical Association. American Pharmaceutical Association. 1914. p. 564. Retrieved 2015-05-04.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":22,"type":"book","title":"Witkop B (1943). \"Zur Konstitution des Yohimbins und seiner Abbauprodukte\" [On the constitution of yohimbine and its breakdown products]. Justus Liebig's Annalen der Chemie (in German). 554 (1): 83–126. doi:10.1002/jlac.19435540108.CS1 maint: Unrecognized language (link)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":23,"type":"book","title":"The Alkaloids: Chemistry and Pharmacology. 32. Academic Press. 1988. p. 564. ISBN 978-0-12-469532-0.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":24,"type":"book","title":"van Tamelen E, Shamma M, Burgstahler A, Tamm R, Aldrich P (1958). \"The Total Synthesis of Yohimbine\". J. Am. Chem. Soc. 80 (18): 5006–5007. doi:10.1021/ja01551a062.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":25,"type":"book","title":"Herlé B, Wanner MJ, van Maarseveen JH, Hiemstra H (November 2011). \"Total synthesis of (+)-yohimbine via an enantioselective organocatalytic Pictet-Spengler reaction\". The Journal of Organic Chemistry. 76 (21): 8907–12. doi:10.1021/jo201657n. PMID 21950549.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":26,"type":"book","title":"Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, et al. (February 2000). \"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states\". Synapse. 35 (2): 79–95. doi:10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X. PMID 10611634.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":27,"type":"book","title":"\"Yohimbine Test Ligand Search\". PDSP Ki Database.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":28,"type":"book","title":"Arthur JM, Casañas SJ, Raymond JR (June 1993). \"Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors\". Biochemical Pharmacology. 45 (11): 2337–41. doi:10.1016/0006-2952(93)90208-E. PMID 8517875.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":29,"type":"book","title":"Kaumann AJ (June 1983). \"Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors\". Naunyn-Schmiedeberg's Archives of Pharmacology. 323 (2): 149–54. doi:10.1007/BF00634263. PMID 6136920.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":30,"type":"book","title":"Baxter GS, Murphy OE, Blackburn TP (May 1994). \"Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle\". British Journal of Pharmacology. 112 (1): 323–31. doi:10.1111/j.1476-5381.1994.tb13072.x. PMC 1910288. PMID 8032658.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":31,"type":"book","title":"\"Yohimbine (PIM 567)\". Inchem.org. Retrieved 2013-05-26.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":32,"type":"book","title":"\"Yohimbine\". DrugBank. University of Alberta. Archived from the original on January 30, 2013. Retrieved 12 April 2014.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":33,"type":"book","title":"Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ (May 2015). \"Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders\". Review. Pharmacology & Therapeutics. 149: 150–90. doi:10.1016/j.pharmthera.2014.12.004. PMC 4380664. PMID 25550231.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":34,"type":"book","title":"McGuire JF, Lewin AB, Storch EA (August 2014). \"Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder\". Review. Expert Review of Neurotherapeutics. 14 (8): 893–910. doi:10.1586/14737175.2014.934677. PMC 4125602. PMID 24972729.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":35,"type":"book","title":"\"Yohimbe Supplement\". National Center for Complementary and Integrative Health. February 2007. Retrieved 2017-08-28.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":36,"type":"book","title":"Andersson KE (September 2001). \"Pharmacology of penile erection\". Review. Pharmacological Reviews. 53 (3): 417–50. PMID 11546836.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":37,"type":"book","title":"\"CFR - Code of Federal Regulations Title 21: Regulations on OTC products\". U.S. Food and Drug Administration.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":38,"type":"book","title":"Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA (March 2016). \"Pharmaceutical quantities of yohimbine found in dietary supplements in the USA\". primary. Drug Testing and Analysis. 8 (3–4): 357–69. doi:10.1002/dta.1849. PMID 26391406.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":39,"type":"book","title":"Saenz de Tejada I, Kim NN, Goldstein I, Traish AM (March 2000). \"Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum\". Review. International Journal of Impotence Research. 12 Suppl 1: S20–25. doi:10.1038/sj.ijir.3900500. PMID 10845761.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":40,"type":"book","title":"Jiofack Tafokou RB (2012). \"Pausinystalia johimbe\". In Lemmens RH, Louppe D, Oteng-Amoako AA. Timbers 2 of Plant Resources of Tropical Africa. 7. Wageningen, Ne: PROTA Foundation. pp. 516–519. ISBN 978-9290814955.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":41,"type":"book","title":"Sunderland TC, Ngo-Mpeck M, Tchoundjeu Z, Laird SA (2002). \"Yohimbe (Pausinstalia johimbe)\". In Shanley P, Pierce AR, Laird SA, Guillén A. Tapping the Green Market: Certification & Management of Non-Timber Forest Products. Earthscan Publications Ltd. pp. 215–224. ISBN 978-1853838712.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":42,"type":"book","title":"\"Quebracho\" is formed from the Spanish words for \"axe breaker'.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":43,"type":"book","title":"Bucher, E.H. (2012). \"Chaco and Caatinga — South American Arid Savannas, Woodlands and Thickets\". In Huntley, B.J.; Walker, B.H. Ecology of Tropical Savannas. Ecological Studies. 42. Springer Science and Business. Media. pp. 54–57. ISBN 978-3642687860.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":44,"type":"book","title":"\"Nombre científico: Aspidosperma quebracho-blanco\". Herbario Digital (in Spanish). CONICET. Retrieved 12 January 2019.CS1 maint: Unrecognized language (link)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":45,"type":"book","title":"Moglia JG, López CR (2001). \"Variabilidad radial de algunos caracteres anatómicos de Aspidosperma quebracho blanco\" [Radial variability of some anatomical characters of Aspidosperma white quebracho]. Bosque (in Spanish). 22 (2): 4. doi:10.4206/bosque.2001.v22n2-01. ISSN 0304-8799.CS1 maint: Unrecognized language (link)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":46,"type":"book","title":"Kent RB (2006). Latin America: Regions and People. Texts in regional geography. Guilford Press. p. 151. ISBN 978-1572309098.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":47,"type":"book","title":"\"The IUCN Red List of Threatened Species\". Retrieved 12 January 2019.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":48,"type":"book","title":"Abel, G.; et al. (2012). Adverse Effects of Herbal Drugs. 3. Springer Science & Business Media. ISBN 978-3642603679.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":49,"type":"book","title":"Bosker G (1995). Emergency Medicine Therapeutics (2 ed.). Mosby, Incorporated. p. 342. ISBN 978-0815109921.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":50,"type":"book","title":"Philippsborn H (2006). Elsevier's Dictionary of Vitamins and Pharmacochemistry. Elsevier. p. 599. ISBN 978-0080488790.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":51,"type":"book","title":"Staff (1983). Food and Drug Administration Consumer. U.S. Department of Health, Education, and Welfare, Public Health Service, Food and Drug Administration. p. 10.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":52,"type":"book","title":"Lewis RA, Hawley GG (2016). Larrañaga MD, Lewis RJ, Lewis R, eds. Hawley's Condensed Chemical Dictionary. John Wiley & Sons. p. 1438. ISBN 978-1118135150.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":53,"type":"book","title":"Jeske AH, ed. (2013). Mosby's Dental Drug Reference - E-Book (11 ed.). Elsevier Health Sciences. pp. Appendix H, e83. ISBN 978-0323172264.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":54,"type":"book","title":"Manske R, Meurant G (1965). The Alkaloids: Chemistry and Physiology. 8. Academic Press. p. 696. ISBN 978-0080865324.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":55,"type":"book","title":"Riviere JE, Papich MG, eds. (2013). Veterinary Pharmacology and Therapeutics (9 ed.). John Wiley & Sons. p. 353. ISBN 978-1118685907.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":56,"type":"book","title":"Yeung AY, Foster S (2003). Encyclopedia of Common Natural Ingredients: Used in Food, Drugs, and Cosmetics (2 ed.). Wiley. p. 431. ISBN 978-0471471288..","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":57,"type":"book","title":"Barger G, Field E (1915). \"Yohimbine (Quebrachine)\". Journal of the Chemical Society, Transactions. 107: 1025. doi:10.1039/CT9150701025.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":58,"type":"book","title":"Hammouda Y, Janot MM, Le Men J (May 1956). \"[Presence of yohimbine (quebrachin) in the roots of Madagascar periwinkle, Lochnera lancea]\". Annales Pharmaceutiques Francaises (in French). 14 (5): 341–4. PMID 13373134.CS1 maint: Unrecognized language (link)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":59,"type":"book","title":"Betz JM (2010). \"Yohimbe\". In Coates PM, Betz JM, Blackman MR, Cragg GM, Levine M, Moss J, White JD. Encyclopedia of Dietary Supplements (2nd ed.). New York and London: Informa Healthcare. p. 861–3. ISBN 9781439819289.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":60,"type":"book","title":"U.S. Anti-Doping Agency Supplement Guide, p. 28.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":61,"type":"book","title":"Doping substances in dietary supplements","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":1902,"auditType":2,"synonyms":null,"showEditTime":"2020.08.25 14:41","auditors":[{"uid":5567290,"name":"人间小太阳","pic":"https://web.archive.org/web/20221028215451/https://cache.soso.com/qlogo/g?b=oidb&k=4xjGfuUZbbjZEI7OAVIVEg&s=100&t=1609215301","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":250,"partnerIdCreateTime":1598322359,"partnerIdPoped":true}],"hasZhishiNav":true,"auditInfos":{"0":[{"versionId":"0","auditTime":1598338079,"auditorId":5567290,"auditUser":{"uid":5567290,"name":"人间小太阳","pic":"https://web.archive.org/web/20221028215451/https://cache.soso.com/qlogo/g?b=oidb&k=4xjGfuUZbbjZEI7OAVIVEg&s=100&t=1609215301","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":250,"partnerIdCreateTime":1598322359,"partnerIdPoped":true},"auditReason":"","auditSuggest":"简单修改","auditResult":2,"auditAnnotations":null}]},"isHistory":false};</script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/aegis.min.js.download"></script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/main_2020092401.js.download"></script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/jquery-1.11.1.min.js.download"></script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/main_2022062701.js.download"></script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/main_66bbe21.js.download"></script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./91.育亨宾 - 搜狗科学百科_files/main_edf0f08.js.download"></script>
</body></html>